<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491553</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-389-2024</org_study_id>
    <secondary_id>ACTRN12618000143224p</secondary_id>
    <nct_id>NCT03491553</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adults With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability and antiviral
      activity of multiple oral doses of GS-9688 in virally suppressed chronic hepatitis B (CHB)
      adults on oral antiviral (OAV) agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With ≥ 1 Log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Log10 IU/mL Decline in qHBsAg From Baseline at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Log10 IU/mL Decline in qHBsAg From Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Log10 IU/mL Decline in qHBsAg From Baseline at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Log10 IU/mL Decline in qHBsAg From Baseline at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qHBsAg (log10 IU/mL) From Baseline at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qHBsAg (log10 IU/mL) From Baseline at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qHBsAg (log10 IU/mL) From Baseline at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qHBsAg (log10 IU/mL) From Baseline at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qHBsAg (log10 IU/mL) From Baseline at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>HBsAg loss is defined as HBsAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Loss at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>HBsAg loss is defined as HBsAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Loss at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>HBsAg loss is defined as HBsAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Loss at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>HBeAg loss is defined as HBeAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Loss at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>HBeAg loss is defined as HBeAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Loss at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>HBeAg loss is defined as HBeAg changing from positive at baseline to negative at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>HBeAg seroconversion is defined as HBeAg loss and HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion at Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>HBeAg seroconversion is defined as HBeAg loss and HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>HBeAg seroconversion is defined as HBeAg loss and HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to 48 Weeks</time_frame>
    <description>Virologic breakthrough is defined as two consecutive visits of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 69 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Drug Resistance Mutations</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Hepatitis B e antigen (HBeAg)-positive CHB, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/Early Discontinuation [ED]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-positive CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive GS-9688 1.5 mg (1 x 1.5 mg tablet) plus placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-positive CHB, GS-9688 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive GS-9688 3 mg (2 x 1.5 mg tablet) for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-negative CHB, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-negative CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive GS-9688 1.5 mg (1 x 1.5 mg tablet) plus placebo for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg-negative CHB, GS-9688 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will remain on their current OAV and receive GS-9688 3 mg (2 x 1.5 mg tablet) for 24 doses. After the 24th dose, participants will continue on their current OAV therapy until the end of study (Week 48/ED).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9688</intervention_name>
    <description>Tablet(s) administered orally once weekly</description>
    <arm_group_label>HBeAg-positive CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_label>HBeAg-positive CHB, GS-9688 3 mg</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, GS-9688 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match (PTM) GS-9688 tablet(s) administered orally once weekly</description>
    <arm_group_label>Hepatitis B e antigen (HBeAg)-positive CHB, Placebo</arm_group_label>
    <arm_group_label>HBeAg-positive CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, Placebo</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, GS-9688 1.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAV Therapy</intervention_name>
    <description>Commercially available HBV OAV treatment(s)</description>
    <arm_group_label>Hepatitis B e antigen (HBeAg)-positive CHB, Placebo</arm_group_label>
    <arm_group_label>HBeAg-positive CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_label>HBeAg-positive CHB, GS-9688 3 mg</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, Placebo</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, GS-9688 1.5 mg</arm_group_label>
    <arm_group_label>HBeAg-negative CHB, GS-9688 3 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study procedures

          -  Adult males and non-pregnant, non-lactating females

          -  Documented evidence of chronic HBV infection with detectable HBsAg levels

          -  On commercially available HBV OAV treatment(s) for at least 6 months with no change in
             regimen for 3 months prior to screening

          -  HBV Deoxyribonucleic acid (DNA) ≤ 20 IU/mL for 6 or more months prior to screening

          -  Screening Electrocardiogram (ECG) without clinically significant abnormalities

        Key Exclusion Criteria:

          -  Extensive bridging fibrosis or cirrhosis

          -  Adults meeting any of the protocol defined exclusionary laboratory parameters at
             screening:

               -  Alanine aminotransferase (ALT) &gt;3x Upper Limit of Normal (ULN)

               -  International normalized ratio (INR) &gt; ULN unless the adult is stable on an
                  anticoagulant regimen

               -  Albumin &lt; 3.5 g/dL

               -  Direct bilirubin &gt;1.5x ULN

               -  Platelet Count &lt; 100,000/uL

               -  Estimated creatinine clearance &lt; 60 mL/min (using the Cockcroft-Gault method)

          -  Co-infection with human immunodeficiency virus, hepatitis C virus or hepatitis D virus

          -  Prior history of hepatocellular carcinoma (HCC) or screening alpha-fetoprotein ≥ 50
             ng/mL without imaging

          -  Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant
             psychiatric illness, severe chronic obstructive pulmonary disease, hemoglobinopathy,
             retinal disease, or are immunosuppressed.

          -  Chronic liver disease of a non-HBV etiology, except for non-alcoholic fatty liver
             disease

          -  Received solid organ or bone marrow transplant

          -  Received prolonged therapy with immunomodulators or biologics within 3 months of
             screening

          -  Use of another investigational agent within 90 days of screening, unless allowed by
             the Sponsor

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

